Markus Lacher, Vice President of R&D
Professional Overview
Markus Lacher is an accomplished R&D and biotechnology executive with extensive experience leading innovative research and development initiatives in the immuno-oncology and cell therapy sectors. As the Vice President of R&D at Notable, he is responsible for overseeing the company's cutting-edge research programs and driving the development of novel therapies to address unmet medical needs.
Experience Summary
Current Role
As the Vice President of R&D at Notable, Markus is responsible for spearheading the company's research and development efforts, managing a team of scientists and researchers, and collaborating with cross-functional stakeholders to accelerate the pipeline of innovative cancer treatments. Under his leadership, the R&D team has made significant strides in advancing the company's portfolio of immuno-oncology and cell-based therapies, with several promising candidates currently in various stages of clinical development.
Career Progression
Prior to his current role, Markus served as the Head of Immuno-Oncology at Notable, where he led the research and development of the company's next-generation immunotherapies. Before joining Notable, he held senior R&D positions at BriaCell Therapeutics Corp. and Cesca Therapeutics, Inc., where he played a pivotal role in the advancement of cell-based cancer therapies. Markus also has entrepreneurial experience, having founded and led T cell Therapeutics, Inc., a biotechnology startup focused on developing novel T-cell-based cancer treatments.
Academic Background
Markus holds a Ph.D. in Immunology from the University of California, San Francisco, where he conducted groundbreaking research on the role of T cells in cancer immunotherapy. His academic achievements include several peer-reviewed publications and presentations at prestigious scientific conferences.
Areas of Expertise
- Immuno-oncology and cell therapy research and development
- Innovative cancer treatment strategies, including CAR-T, TCR, and other cell-based therapies
- Preclinical and clinical development of novel therapeutic candidates
- Translational research and the application of cutting-edge technologies to drug discovery
- Cross-functional collaboration and team leadership in the biotechnology industry
Professional Impact
Throughout his career, Markus has made significant contributions to the advancement of cancer research and the development of innovative therapies. His research has led to the identification of novel targets and the advancement of several promising drug candidates, some of which are now in late-stage clinical trials. Markus is also recognized as a thought leader in the field of immuno-oncology, regularly sharing his expertise through invited presentations and participation in industry conferences.
Conclusion
With his deep expertise in immuno-oncology and cell therapy research, proven track record of driving R&D initiatives, and strong collaborative leadership skills, Markus Lacher is well-positioned to continue his impactful work at Notable, advancing the company's mission of developing transformative cancer treatments and improving patient outcomes.
